The world’s first drugs designed to stop cancer cells becoming resistant to treatment could be available within the next decade, scientists have said.
A £75m investment to develop the drugs has been announced by the Institute of Cancer Research (ICR).
Chief executive Prof Paul Workman said cancer’s ability to adapt to drugs is the biggest challenge in treatment.
The new drugs could make cancer a “manageable” disease in the long term and “more often curable”, he said.
Researchers say existing treatments such as chemotherapy sometimes fail because the deadliest cancer cells adapt and survive, causing the patient to relapse.
Prof Workman said: “Cancer’s ability to adapt, evolve and become drug resistant was the cause of the vast majority of deaths from the disease and the biggest challenge we face in overcoming it.”
He said the institute was “changing the entire way we think about cancer” to focus on anticipating the way cancer cells will evolve to prevent them from becoming resistant to drugs.
The ICR aims to attract a further £15m of funding for its new Centre for Drug Discovery at its campus in Sutton, south London, which is intended to bring together almost 300 scientists from different fields.
All cancers are constantly evolving and that is a major problem because patients relapse if their cancer develops resistance to therapy.
The approach by the Institute of Cancer Research is to harness the process of evolution, to turn to the theories of Charles Darwin in the hunt for new therapies.
One idea is to develop drugs that limit a cancer’s ability to evolve.
Another is “evolutionary herding” that guides a cancer’s development into a state that makes it more vulnerable to drugs.
Or combinations of therapies could present an impossible hurdle for cancer to overcome.
Early-stage experiments using these ideas have had promising results, but any changes to the way patients are treated are at least a decade away.
Scientists aim to use new approaches including multidrug combination treatments and artificial intelligence to predict and influence the evolution of cancer cells, creating weaknesses that treatments can exploit